Treace Medical Concepts, Inc.

NasdaqGS:TMCI Stock Report

Market Cap: US$433.6m

Treace Medical Concepts Management

Management criteria checks 2/4

Treace Medical Concepts' CEO is John Treace, appointed in Jul 2014, has a tenure of 10.42 years. total yearly compensation is $8.42M, comprised of 8.1% salary and 91.9% bonuses, including company stock and options. directly owns 18.7% of the company’s shares, worth $81.09M. The average tenure of the management team and the board of directors is 3.2 years and 6.9 years respectively.

Key information

John Treace

Chief executive officer

US$8.4m

Total compensation

CEO salary percentage8.1%
CEO tenure10.4yrs
CEO ownership18.7%
Management average tenure3.2yrs
Board average tenure6.9yrs

Recent management updates

Recent updates

Further Upside For Treace Medical Concepts, Inc. (NASDAQ:TMCI) Shares Could Introduce Price Risks After 84% Bounce

Dec 03
Further Upside For Treace Medical Concepts, Inc. (NASDAQ:TMCI) Shares Could Introduce Price Risks After 84% Bounce

Is Treace Medical Concepts (NASDAQ:TMCI) Using Debt In A Risky Way?

Oct 26
Is Treace Medical Concepts (NASDAQ:TMCI) Using Debt In A Risky Way?

Treace Medical Concepts, Inc. (NASDAQ:TMCI) Screens Well But There Might Be A Catch

Aug 02
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Screens Well But There Might Be A Catch

Treace Medical Concepts (NASDAQ:TMCI) Has Debt But No Earnings; Should You Worry?

Jun 28
Treace Medical Concepts (NASDAQ:TMCI) Has Debt But No Earnings; Should You Worry?

Treace Medical Concepts: Facing Increasing Competitive Pressure

Jun 14

Market Still Lacking Some Conviction On Treace Medical Concepts, Inc. (NASDAQ:TMCI)

Apr 05
Market Still Lacking Some Conviction On Treace Medical Concepts, Inc. (NASDAQ:TMCI)

Does Treace Medical Concepts (NASDAQ:TMCI) Have A Healthy Balance Sheet?

Feb 09
Does Treace Medical Concepts (NASDAQ:TMCI) Have A Healthy Balance Sheet?

Why Investors Shouldn't Be Surprised By Treace Medical Concepts, Inc.'s (NASDAQ:TMCI) 31% Share Price Surge

Jan 04
Why Investors Shouldn't Be Surprised By Treace Medical Concepts, Inc.'s (NASDAQ:TMCI) 31% Share Price Surge

Market Cool On Treace Medical Concepts, Inc.'s (NASDAQ:TMCI) Revenues Pushing Shares 46% Lower

Nov 11
Market Cool On Treace Medical Concepts, Inc.'s (NASDAQ:TMCI) Revenues Pushing Shares 46% Lower

Analysts Are Updating Their Treace Medical Concepts, Inc. (NASDAQ:TMCI) Estimates After Its Second-Quarter Results

Aug 13
Analysts Are Updating Their Treace Medical Concepts, Inc. (NASDAQ:TMCI) Estimates After Its Second-Quarter Results

CEO Compensation Analysis

How has John Treace's remuneration changed compared to Treace Medical Concepts's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$62m

Jun 30 2024n/an/a

-US$64m

Mar 31 2024n/an/a

-US$55m

Dec 31 2023US$8mUS$684k

-US$50m

Sep 30 2023n/an/a

-US$48m

Jun 30 2023n/an/a

-US$42m

Mar 31 2023n/an/a

-US$47m

Dec 31 2022US$4mUS$568k

-US$43m

Sep 30 2022n/an/a

-US$45m

Jun 30 2022n/an/a

-US$39m

Mar 31 2022n/an/a

-US$27m

Dec 31 2021US$688kUS$410k

-US$21m

Sep 30 2021n/an/a

-US$12m

Jun 30 2021n/an/a

-US$8m

Mar 31 2021n/an/a

-US$5m

Dec 31 2020US$392kUS$316k

-US$4m

Compensation vs Market: John's total compensation ($USD8.42M) is above average for companies of similar size in the US market ($USD2.16M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.

CEO

John Treace (52 yo)

10.4yrs

Tenure

US$8,422,635

Compensation

Mr. John T. Treace Founded Treace Medical Concepts, Inc. in 2014 and has been its Chief Executive Officer and Director since July 1, 2014. Before that, Mr. Treace served as Senior Vice President of U.S. Sa...

Leadership Team

NamePositionTenureCompensationOwnership
John Treace
CEO, Founder & Director10.4yrsUS$8.42m18.7%
$ 81.1m
Mark Hair
Chief Financial Officer4.3yrsUS$4.69m0.031%
$ 134.7k
Aaron Berutti
Senior Vice President of Sales3.3yrsUS$3.26m0.0066%
$ 28.4k
Terry Lubben
Chief Operations & Supply Chain Officer3.3yrsno datano data
Taylor Erickson
Chief Information Officer2.8yrsno datano data
Scot Elder
Chief Legal & Compliance Officer and Corporate Secretary3.2yrsno data0.050%
$ 215.6k
Nathan Minnich
Senior Vice President of Marketing1.3yrsno datano data
Daniel Owens
Chief Human Resources Officer3.8yrsno datano data
Sean Scanlan
Chief Innovation Officer1.9yrsno data0.056%
$ 242.8k
Shana Zink
Senior Vice President of Clinical Affairs & Reimbursementno datano datano data
Rachel Osbeck
Senior Vice President of Quality Assurance & Regulatory Affairsno datano datano data
Guy Guglielmino
Chief Commercial Officerno datano datano data

3.2yrs

Average Tenure

52yo

Average Age

Experienced Management: TMCI's management team is considered experienced (3.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
John Treace
CEO, Founder & Director10.4yrsUS$8.42m18.7%
$ 81.1m
Lawrence Hamilton
Independent Director4.1yrsUS$214.79k0.0081%
$ 35.1k
James Treace
Chairman of the Board10.5yrsUS$94.74k2.86%
$ 12.4m
Richard Mott
Independent Director9.8yrsUS$197.26k1.7%
$ 7.4m
John Bakewell
Independent Director4.1yrsUS$214.79k0.77%
$ 3.3m
Deepti Jain
Independent Director3.2yrsUS$209.79k0.050%
$ 214.6k
Paul Dayton
Member of the Surgeon Advisory Boardno datano datano data
William DeCarbo
Member of the Surgeon Advisory Boardno datano datano data
Daniel Hatch
Member of the Surgeon Advisory Boardno datano datano data
J.P. McAleer
Member of the Surgeon Advisory Boardno datano datano data
W. Smith
Member of the Surgeon Advisory Boardno datano datano data
Robert Santrock
Member of the Surgeon Advisory Boardno datano datano data

6.9yrs

Average Tenure

63.5yo

Average Age

Experienced Board: TMCI's board of directors are considered experienced (6.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 08:51
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Treace Medical Concepts, Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael GormanBTIG
Robert MarcusJ.P. Morgan
Richard NewitterLeerink Partners LLC